CORTCorcept Therapeutics Incorporated
Is the price fair?
A demanding price: at the top of its own P/E range and rich vs its sector.
Priced for ~25% a year FCF growth. Roughly in line with its three-year revenue growth of 25% a year.
Expensive vs its own history: P/E 201.8 vs a 26.6 median over 40 quarters (+658% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CORT's price assumes
Corcept Therapeutics Incorporated trades at 288× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 15.3× the median: the market pays up for this one
- Price / sales
- 11.9
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; the business has delivered −7.4% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 14.0
- EV / EBIToperating margin 0.77%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 11.5
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $107M
- Market capitalisation
- $9.10B
- 3-year revenue growth
- +25%
- 3-year free cash flow growth
- −7.4%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 202× today against a 26.6× median |
| 52-week range | $32.15 – $123.53 |
| Today | $121.12 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.